Table 2.

Clinical and safety outcomes for patients with virtual follow-up.

Author	Year	Re-admission	In person review required	Recurrence	Morbidity and mortality
Beaver et al.	2012			2/25 control and 1/25 in TM.
Beaver et al.	2017			5/129 TM, 5/130 control
Cerfolio et al.	2019	No emergency readmissions.	No in-person reviews required.		No major morbidity. Minor morbidity: 10/56. No 30- or 90-day mortality.
Mole et al.	2019			13/142 patients.	5-year mortality: 4/142
Siddika et al.	2015				5-year mortality: 7.3%–21.2% based on tumor type.
Uppal et al.	2022	90-day readmission: 16.3% TM, 16.5% control	14/98 (14.2%) TM		No difference in mortality.